This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
SpringWorks Gets CHMP Nod for Mirdametinib in Rare Disease
by Zacks Equity Research
SWTX wins CHMP backing for mirdametinib in NF1-PN. EU nod is expected in the third quarter of 2025.
HALOPositive Net Change LXRXNegative Net Change AMRNNegative Net Change
biotechs
MRNA Seeks FDA Nod for Updated COVID-19 Vaccine
by Zacks Equity Research
Moderna files with FDA for updated Spikevax aimed at the LP.8.1 variant, which makes up 70% of U.S. COVID-19 cases.
PFEPositive Net Change MRNANegative Net Change NVAXNegative Net Change BNTXPositive Net Change
biotechs medical messenger-rna pharmaceuticals vaccines
Roche Gets CHMP Nod for Itovebi Combo in the EU for Breast Cancer
by Zacks Equity Research
RHHBY's Itovebi combo wins CHMP backing for PIK3CA-mutated breast cancer, showing strong survival benefits in phase III INAVO120 study.
AZNNegative Net Change RHHBYNegative Net Change PFEPositive Net Change BAYRYPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
GILD Announces Positive Data on Trodelvy in First-Line Breast Cancer
by Zacks Equity Research
Gileads Trodelvy shows significant improvement in PFS in phase III ASCENT-03 trial for first-line metastatic TNBC, reinforcing potential as backbone therapy.
NVSPositive Net Change PFEPositive Net Change MRKPositive Net Change GILDPositive Net Change
biotechnology biotechs medical pharmaceuticals
3 Stocks Targeting Weight Loss Market With Cannabinoid-Based Therapies
by Sundeep Ganoria
NVO, CRBP and SKYE are tapping into the booming obesity market with novel CBD-based therapies, offering alternatives amid intensifying GLP-1 competition.
NVOPositive Net Change LLYNegative Net Change CRBPNegative Net Change SKYENegative Net Change
biotechs marijuana medical pharmaceuticals
Bayer Gets CHMP Nod for Eylea 8 mg in the EU for 2 Major Eye Diseases
by Zacks Equity Research
BAYRY's Eylea 8 mg gets CHMP nod in EU, promising 6-month dosing for nAMD and DME with strong 3-year efficacy and safety data.
REGNPositive Net Change BAYRYPositive Net Change HALOPositive Net Change AMRNNegative Net Change
biotechnology biotechs medical pharmaceuticals
EXEL Reports Superior Efficacy Data From Kidney Cancer Study Cohort
by Zacks Equity Research
Exelixis' zanzalintinib/Opdivo combo shows superior efficacy for treating kidney cancer in an expansion cohort of the phase Ib/II STELLAR-002 study.
BMYPositive Net Change BAYRYPositive Net Change EXELPositive Net Change AMRNNegative Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
Is it a Good Idea to Invest in Immunocore Stock Right Now?
by Zacks Equity Research
IMCR revenues surge on robust Kimmtrak sales performance. The momentum is likely to continue in 2025.
BMYPositive Net Change CRMDNegative Net Change IMCRPositive Net Change
biotechs
FDA Approves GSK's Nucala for Expanded Use in COPD
by Zacks Equity Research
GSK's Nucala wins FDA nod for COPD with eosinophilic phenotype, marking its fifth indication and strengthening its respiratory portfolio.
REGNPositive Net Change SNYNegative Net Change GSKPositive Net Change VRNANegative Net Change
biotechs medical pharmaceuticals
Biotech Stock Roundup: BMRN to Acquire INZY, NVAX Gains on Vaccine Approval & More
by Ekta Bagri
BMRN and NVAX are in the spotlight this week following announcement agreement and regulatory update.
BMRNNegative Net Change MRNANegative Net Change NVAXNegative Net Change PRMEPositive Net Change
biotechnology biotechs medical pharmaceuticals
MRNA Stock Down on Withdrawal of FDA Filing for COVID-Flu Combo Shot
by Zacks Equity Research
Moderna's voluntary withdrawal of the filing stems from the FDA's request for vaccine efficacy data from a phase III study on the experimental flu shot.
SNYNegative Net Change PFEPositive Net Change MRNANegative Net Change NVAXNegative Net Change
biotechs medical messenger-rna pharmaceuticals vaccines
CGON Stock Rallies 27% in a Month on Bladder Cancer Study Success
by Zacks Equity Research
CG Oncology stock surges 27% in a month following superior efficacy data from its phase III study of cretostimogene for a bladder cancer indication.
JNJPositive Net Change MRKPositive Net Change IBRXPositive Net Change CGONPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
ARMP Soars 72% in a Month Following Infectious Disease Study Success
by Zacks Equity Research
Armata Pharmaceuticals stock surges 72% in a month following superior efficacy results from a phase Ib/IIa study of AP-SA02 for treating an infectious disease.
BAYRYPositive Net Change HALOPositive Net Change AMRNNegative Net Change ARMPPositive Net Change
biotechnology biotechs medical pharmaceuticals
AMGN Down 10% in 3 Months: How to Play the Stock as Tariff Woes Linger
by Kinjel Shah
AMGN's consistent top-line growth, an interesting pipeline and rising estimates are good enough reasons to stay invested in the stock for now.
JNJPositive Net Change NVOPositive Net Change LLYNegative Net Change AMGNPositive Net Change
biotechs
MRNA, PFE Stocks Jump Despite FDA's Stricter Standards for COVID-19 Shots
by Sundeep Ganoria
Though the new FDA rules limit access to COVID-19 booster vaccines, the commitment to high-risk groups lifts Moderna, Pfizer and BioNTech stocks.
PFEPositive Net Change MRNANegative Net Change BNTXPositive Net Change
biotechs medical messenger-rna pharmaceuticals vaccines
Gilead Sciences vs GSK: Which HIV Drugmaker is a Smarter Buy Now?
by Ekta Bagri
At current levels, we recommend prospective investors to opt for GSK as compared to GILD on the back of a strong and wide portfolio, upcoming product launches, promising pipeline candidates and recent positive estimate revisions
GSKPositive Net Change GILDPositive Net Change
biotechnology biotechs medical pharmaceuticals
BIAF Stock Rises Post Q1 Earnings Despite Revenue Decline
by Zacks Equity Research
bioAffinity's first-quarter 2025 results show CyPath Lung sales growth and cost cuts despite a drop in total revenues and a wider quarterly net loss.
BIAFPositive Net Change
biotechnology biotechs earnings medical
CRISPR Therapeutics Inks Collaboration Deal to Develop siRNA Therapies
by Zacks Equity Research
CRSP enters into a strategic partnership with Sirius Therapeutics for developing novel siRNA Therapies.
VRTXNegative Net Change HALOPositive Net Change AMRNNegative Net Change CRSPNegative Net Change
biotechs
REGN Signs $256M Buyout Deal With 23andMe to Boost Genomics Research
by Zacks Equity Research
Regeneron is set to acquire 23andMe assets for $256 million to boost genetic drug discovery. The transaction is expected to close by third-quarter 2025.
REGNPositive Net Change BAYRYPositive Net Change HALOPositive Net Change ALLONegative Net Change
biotechnology biotechs dna-sequencing genomics medical pharmaceuticals
Amgen vs Bristol Myers: Which Biotech Giant Has Better Prospects?
by Ekta Bagri
At current levels, we believe AMGN scores above BMY, buoyed by solid fundamentals and recent positive estimate revisions.
BMYPositive Net Change AMGNPositive Net Change
biotechnology biotechs cancer medical pharmaceuticals
Novo Nordisk Shares Dip 3% on Sudden CEO Transition Announcement
by Zacks Equity Research
NVO stock declines 3% as the company announces that Lars Fruergaard Jorgensen will be stepping down as the CEO.
NVOPositive Net Change LLYNegative Net Change AMGNPositive Net Change VKTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
NVAX Stock Surges on Securing FDA Approval for COVID-19 Vaccine
by Zacks Equity Research
The FDA grants full approval to Novavax's protein-based COVID-19 vaccine after nearly a two-month delay, albeit with some new conditions.
SNYNegative Net Change PFEPositive Net Change MRNANegative Net Change NVAXNegative Net Change
biotechs medical messenger-rna pharmaceuticals vaccines
ACAD Stock Soars as US Court Rules in Favor of Key Nuplazid Patent
by Zacks Equity Research
Acadia stock jumps 27% after winning a key patent case for Nuplazid, which will protect the drug's U.S. sales from generic erosion till 2038.
BAYRYPositive Net Change HALOPositive Net Change ACADPositive Net Change NTLANegative Net Change
biotechnology biotechs medical pharmaceuticals
BioMarin Offers to Buy Inozyme for $270M to Boost Enzyme Therapy Biz
by Zacks Equity Research
BMRN's acquisition of INZY is set to add a late-stage enzyme replacement therapy for a rare genetic condition. The deal is likely to be closed by September.
BMRNNegative Net Change AGENPositive Net Change ADPTNegative Net Change
biotechs medical pharmaceuticals
Incyte Gets FDA Approval for Zynyz in New Cancer Indication
by Zacks Equity Research
The FDA approves INCY's Zynyz both as monotherapy and in combination with chemotherapy for treating advanced anal cancer.
NVSPositive Net Change INCYPositive Net Change HALOPositive Net Change NTLANegative Net Change
biotechs